Enabling A Four-Fold Increase In Titer For mAb Manufacturing Using Syngene's Platform Process

Efficient monoclonal antibody (mAb) production is critical for meeting the growing demand for advanced biologic therapies, particularly in oncology. However, achieving high titers while maintaining product quality and meeting tight development timelines remains a significant challenge for manufacturers. Explore how a structured, platform-driven upstream development strategy addressed these issues by integrating clone selection, process optimization, and scalable production techniques. Through a combination of monoclonal screening, design of experiments (DoE), and bioreactor-based optimization, high-performing clones were identified and cultivated under refined conditions. The approach enabled rapid process improvements and minimized experimental redundancy, accelerating development without compromising quality. Subsequent scale-up demonstrated robust performance, achieving substantial titer gains and consistent product attributes. Overall, the methodology highlights how leveraging platform expertise and data-driven decision-making can transform manufacturing efficiency, reduce costs, and support faster progression toward clinical and commercial production.